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Angiopoietins (Ang, also known as Angpt), ligands of the endothe-
lial TEK (Tie2) tyrosine kinase receptor, have been associated with 
vascular remodeling and stabilization signals in angiogenesis (1,2). 
In the blood vascular endothelium, Ang1 exerts agonistic functions 
via increased phoshorylation of Tie2 (3). Both Ang1 and Tie2 are 
essential for the remodeling of a functional blood vessel network 
during embryogenesis (4–6). They also promote various functions 
characteristic of the mature blood vasculature, such as endothelial 
cell survival (7). Until very recently, Ang2 was considered primarily 
as a Tie2 antagonist, being expressed mainly at sites of vascular 
remodeling  where  it  destabilizes  the  vascular  endothelium  (8). 
However, evidence is emerging that Ang2 may have different roles 
in the vasculature depending on the context (9,10). The antago-
nistic function of Ang2 is required for normal development of ret-
inal vessels during ocular angiogenesis (11), whereas its Tie2 agonist 
activity is required for normal lymphatic vascular development (12).
Ang2 expression is increased in activated and hypoxic vascular 
endothelial cells in tumors, where it acts as an Ang1 antagonist and 
promotes tumor angiogenesis and growth (13–16). Nasarre et al. 
(17) described an initial transient inhibition of tumor growth and 
angiogenesis  in  mice  with  genetically  ablated  Ang2  (17).  The 
blockade of Ang2 with antibodies and peptide-Fc fusion proteins 
results in suppression of primary tumor growth and angiogenesis 
(16,18,19).  Notably,  elevated  circulating  Ang2  in  patients  with 
pancreatic ductal adenocarcinoma was associated with the extent of 
lymphatic metastasis (20). However, very little is known about the 
effects of Ang2 inhibition on metastasis. Because the formation of 
metastases is often crucial for the prognosis of patients, it is impor-
tant to evaluate the effect of Ang2 targeting on tumor cell dis-
semination  and  the  development  of  metastases.  Thus,  we 
investigated the effect of Ang2 on tumor progression and metas-
tasis using several different model systems.
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  Background  Angiopoietin-2 (Ang2), a ligand for endothelial TEK (Tie2) tyrosine kinase receptor, is induced in hypoxic endo-
thelial cells of tumors, where it promotes tumor angiogenesis and growth. However, the effects of Ang2 on 
tumor lymphangiogenesis and metastasis are poorly characterized.
  Methods  We addressed the effect of Ang2 on tumor progression and metastasis using systemic Ang2 overexpression in 
mice carrying tumor xenografts, endothelium-specific overexpression of Ang2 in VEC-tTA/Tet-OS-Ang2 transgenic 
mice implanted with isogenic tumors, and administration of Ang2-blocking antibodies to tumor-bearing immuno-
deficient mice. Fisher’s exact test was used for analysis of metastasis occurrence, and repeated measures one-way 
analysis of variance was used for the analysis of primary tumor growth curves. Unpaired t test was used for all 
other analyses. All statistical tests were two-sided.
  Results  Adenoviral expression of Ang2 increased lymph node and lung metastasis in tumor xenografts. The metastatic 
burden in the lungs was increased in transgenic mice in which Ang2 expression was induced specifically in the 
vascular endothelium (tumor burden per grid, VEC-tTA/Tet-OS-Ang2 mice [n = 5] vs control mice [n = 4]: 45.23 vs 
12.26 mm2, difference = 32.67 mm2, 95% confidence interval = 31.87 to 34.07, P < .001). Ang2-blocking antibodies 
reduced lymph node and lung metastasis, as well as tumor lymphangiogenesis, and decreased tumor cell homing 
to the lungs after intravenous injection. In the lung metastases, Ang2 overexpression decreased endothelial integrity, 
whereas the Ang2-blocking antibodies improved endothelial cell–cell junctions and basement membrane contacts of 
metastasis-associated lung capillaries. At the cellular level, the Ang2-blocking antibodies induced the internalization 
of Ang2-Tie2 receptor complexes from endothelial cell–cell junctions in endothelial–tumor cell cocultures.
 Conclusion  Our results indicate that blocking Ang2 inhibits metastatic dissemination in part by enhancing the integrity of 
endothelial cell–cell junctions.
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Methods
Mice
Six- to eight-week-old female severe combined immunodeficient 
(SCID) and nu/nu BALB/c mice were obtained from Harlan 
Laboratories (Venray, The Netherlands) and 8- to 12-week-old 
NOD SCID gamma (NSG) mice (stock no. 005557) were obtained 
from the Jackson Laboratory (Bar Harbor, ME). VEC-tTA/Tet-
OS-Ang2 transgenic mice and their littermate controls were used 
in the experiments. The TET-OS-Ang2 responder construct was 
made  by  polymerase  chain  reaction  cloning  of  the  full-length 
mouse  Ang2  open  reading  frame  using  the  cDNA  (GenBank 
NW_001030882.1) downstream of the TET-responsive promoter 
in the pTET-OS-vector [described in (21,22) and Supplementary 
Tables 1 and 2, available online]. Transgenic mouse lines were 
generated by injection of the 2.7-kb expression cassette from the 
vector into fertilized mouse oocytes of the strain FVB/NIH. The 
driver VE-cadherin-tTA [VEC-tTA, (23)] and responder trans-
genic mouse lines were bred together to obtain double transgenic 
VEC-tTA/Tet-OS-Ang2 offspring. To overcome the embryonic 
lethality attributable to endothelial Ang2 overexpression in double 
transgenic embryos [(8) and our unpublished data], Ang2 expres-
sion  was  repressed  during  the  entire  pregnancy.  Tetracycline 
(Sigma-Aldrich, St Louis, MO) at 2.0 mg/mL in 5% sucrose was 
added to the drinking water of pregnant females, starting at the 
time of mating and until birth, when Ang2 expression was induced 
by discontinuation of tetracycline administration. Single transgenic 
or wild-type littermates were used as controls for double transgenic 
mice. None of the control mice displayed any obvious phenotype. 
The National Board for Animal Experiments at the Provincial State 
Office of Southern Finland approved all experiments, which were 
performed in accordance with the Finnish legislation regarding the 
humane care and use of laboratory animals.
Cell Culture
The human lung cancer cell line NCI-H460-LNM35 (hereafter 
LNM35)  is  the  previously  used  and  characterized  luciferase-
tagged subline of NCI-H460-N15, a human non–small cell carci-
noma of the lung (24); Lewis lung carcinoma (LLC) and HeLa 
cells were purchased from the American Type Culture Collection 
(ATCC, Manassas, VA) and luciferase-tagged B16-F10 melanoma 
cells were obtained from Caliper Life Sciences Inc (Hopkinton, MA)   
(used  in  passages  below  30).  LNM35  cells  were  maintained  in 
RPMI-1640 medium supplemented with 2 mM L-glutamine, peni-
cillin (100 U/mL), streptomycin (100 µg/mL), and 10% fetal calf 
serum (PromoCell, Heidelberg, Germany). LLC, HeLa, and lucif-
erase-tagged  B16-F10  melanoma  cells  were  maintained  in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
2 mM L-glutamine, penicillin (100 U/mL), streptomycin (100 µg/
mL), and 10% fetal calf serum (PromoCell). Human dermal micro-
vascular lymphatic endothelial cells (LECs) and blood microvascular 
endothelial cells (BECs) (PromoCell) were maintained on fibronec-
tin-coated dishes in Endothelial Cell Basal Medium MV (ECBM; 
PromoCell) with growth supplements provided by the manufacturer 
and used in passages 2–6. Vascular endothelial growth factor-C [100 
ng/mL, (25)] was added to the LEC growth medium. For stimula-
tion, 200 ng/µL COMP-Ang1 [Cartilage oligomeric matrix protein-
Ang1, (26)] was added to the endothelial cells for 30 minutes.
Antibody Inhibition of Tumor Growth
Luciferase-tagged LNM35 tumor cells (5 × 10
6 cells per mouse) 
were implanted into SCID or nu/nu BALB/c mice anesthetized 
with  ketamine  (Ketaminol;  Orion  Pharma,  Espoo,  Finland;  or 
Ketalar; Pfizer, New York, NY) and xylazine (Rompun et; Bayer 
Healthcare, Leverkusen, Germany). Once the primary tumor vo-
lumes reached 150–200 mm
3, the mice (n = 8–10 per group) were 
randomly assigned to receive an intraperitoneal injection of the 
Ang2-blocking antibody [MEDI3617; MedImmune, Gaithersburg, 
MD; (27)] at a dose of 10 mg/kg, or an equal dose of control human 
immunoglobulin G (hIgG). Thereafter, the intraperitoneal admin-
istration of the antibodies and tumor diameter measurements were 
repeated  every  second  day.  At  day  16,  the  primary  tumors  and 
inguinal regional lymph nodes were excised, weighed, imaged for 
bioluminescence, measured in three dimensions with a digital cal-
iper, photographed, and processed for histological analysis.
Tumor Assays Using AdAng2
Luciferase-tagged  LNM35  cells  were  implanted  subcutaneously 
into female SCID mice (n = 9–10 per group), followed by intravenous 
CONTEXTS AND CAVEATS
Prior knowledge
Angiopoietins  (Ang)  are  ligands  of  the  Tie2  tyrosine  kinase  re-
ceptor and function in vascular remodeling during embryogenesis. 
Ang2 is also overexpressed in hypoxic vascular endothelial cells in 
tumors and promotes tumor angiogenesis and growth. However, 
the mechanisms of Ang2 action in tumor progression and metasta-
sis are poorly known.
Study design
The effects of Ang2 on angiogenesis, tumor growth, and metasta-
sis in lungs were studied by systemic and endothelial cell–specific 
Ang2  overexpression  in  mice  carrying  tumor  xenografts  and  in 
transgenic  mice  implanted  with  isogenic  tumors.  The  effect  of 
Ang2 inhibition was studied with anti-Ang2 antibodies in tumor-
bearing immunodeficient mice.
Contribution
Ang2  increased  tumor  metastasis  at  least  in  part  by  promoting 
endothelial disruption and increasing tumor cell translocation and 
homing to target organs. Ang2 inhibition also attenuated tumor 
lymphangiogenesis, dissemination of tumor cells via the lymphatic 
vessels, and tumor cell colonization of the lungs.
Implication
Ang2 may promote metastasis in part by disrupting the integrity of 
endothelial cell–cell junctions.
Limitations
Rapidly  growing  tumors  were  used  in  the  models.  The  dose–
response range was not evaluated, and because of the rapid tumor 
growth and treatment schedules, possible adverse effects related 
to the treatment may have gone unnoticed. It remains to be inves-
tigated if the Ang2 antibodies can inhibit metastatic colonization of 
other tissues besides the lungs.
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administration  of  recombinant  in  vitro  tested  AdAng2  (28)  or 
AdLacZ, and the primary tumor growth was analyzed as described 
above. At 14 days, D-luciferin (Synchem, Felsberg, Germany) was 
administered intraperitoneally at the dose of 150 mg/kg, followed 
by  imaging  for  bioluminescence  10  minutes  after  injection. 
Photonic signal intensities were quantified using the Living Image 
software (Xenogen Corporation, Alameda, CA). At 3 weeks, the 
primary tumors and the lymph nodes were excised, imaged for 
bioluminescence,  weighed,  measured  for  volume  with  a  digital 
caliper, and processed for histology.
To evaluate lung metastasis, SCID mice (n = 3–6 per group) 
were killed at 4 weeks after the removal of the primary tumors at 
3 weeks, and the lungs were weighed and their bioluminescence 
signal was measured. The bioluminescent signal intensity emitted 
from the metastatic foci was quantified with Living Image Software 
(Xenogen Corporation). The area of region of interest was kept 
constant for all the samples.
Lung Colonization Experiments
SCID or NSG mice (n = 4 in each group) were injected intrave-
nously  with  adenoviruses  encoding  angiopoietin-2  (AdAng2)  or 
b-galactosidase (AdLacZ) 2 days before systemic inoculation of 
green fluorescent protein (GFP)–tagged LNM35 cells, and lung 
colonization  was  analyzed  4  days  thereafter  with  fluorescent   
microscopy. To evaluate metastatic growth at later time points, 
B16-F10  or  LNM35  cells  were  implanted  intravenously  into 
AdAng2- and AdLacZ-treated mice, and the lungs were excised at 
2  (B16-F10)  or  3  (LNM35)  weeks,  weighed,  imaged  under  a 
microscope, and processed for histology. Ang2-blocking antibody 
(10 mg/kg) or an equal amount of hIgG were administered intra-
venously  into  the  mice  every  second  day  starting  at   
4 days before systemic injection of the GFP- or luciferase-tagged 
LNM35 cells. The lungs of the mice injected with fluorescently 
tagged tumor cells were analyzed 8 days after tumor cell inoculation 
by microscopy (Leica MZFLIII, Leica Microsystems, Vienna, 
Austria). The homing of luciferase-positive LNM35 tumor cells 
into the lungs of mice treated with Ang2-blocking antibodies or 
hIgG was evaluated by bioluminescence imaging ex vivo at 5 days. 
The extent of lung colonization of systemically administered B16-
F10  cells  in  Ang2-blocking  antibody  vs  hIgG-treated  mice  was 
assessed at 2 weeks, as described above.
In experiments using the inducible transgenic mouse model, 
B16-F10 melanoma cells (1 × 10
5 cells) were inoculated intrave-
nously into the conditionally transgenic Ang2 mice and their litter-
mate  controls,  and  the  lungs  were  analyzed  3  weeks  after  the 
implantation.
Transmission Electron Microscopy
Lung specimens containing melanoma cell colonies from Ang2-
overexpressing, wild-type C57Bl/6J, Ang2-blocking antibody-treated, 
and human serum albumin (HSA) control NSG mice (three mice 
per group) were fixed in 1% glutaraldehyde and 4% formaldehyde 
in  0.1  M  phosphate  buffer,  pH  7.4,  postfixed  in  1%  osmium   
tetroxide, dehydrated in acetone, and embedded in Epon LX112 
(Ladd  Research  Industries,  Williston,  VT).  Sections  of  1.0  µm 
were stained with toluidine blue for histological analysis, and 80-
nm  sections  were  cut  with  a  Leica  Ultracut  UCT  microtome 
(Leica  Microsystems,  Vienna,  Austria)  At  least  three  specimens 
from each mouse were examined using a Philips CM100 transmis-
sion  electron  microscope.  Metastasis-associated  capillaries,  the 
extent  of  endothelial  cell  attachment  from  the  basement  mem-
brane, and the morphology of endothelial cell–cell junctions were 
assessed and quantified from the samples. Images were captured 
with  a  Morada  CCD  camera  (Olympus  Soft  Imaging  Solutions 
GMBH, Munster, Germany).
Retinal Angiogenesis Assay
For the retina experiments, the Naval Medical Research Institute 
(NMRI) pups (n = 3–4 per group) were subcutaneously injected 
with 30 mg/kg of Ang2-blocking antibody or hIgG during postna-
tal  day  (P)0–P4,  killed  on  P5,  and  the  eyes  were  collected  for 
analysis. Blood vessels in the retinas were visualized using biotinyl-
ated Griffonia simplicifolia lectin (Vector Laboratories, Burlingame, 
CA), followed by immunostaining. The following primary anti-
bodies were used: rat anti-mouse Tie2 (TEK4; eBiosciences, San 
Diego, CA; 1:200) and rabbit anti-mouse neural/glial antigen 2 
(NG2, MAB5384; Millipore, Billerica, MA; 1:1000). The primary 
antibodies  were  detected  with  the  appropriate  Alexa  secondary 
antibody  conjugates  (Molecular  Probes,  Invitrogen,  Carlsbad,   
CA). The samples were analyzed with a confocal microscope (Zeiss 
LSM 5 Duo (Carl Zeiss AG, Oberkochen, Germany), objectives 
×10 with NA 0.45, oil objectives ×40 with NA 1.3 and ×63 with NA 
1.4) by using multichannel scanning in frame mode. The pinhole 
diameter was set at one Airy unit for detection of the Alexa 488 
signal and was adjusted for identical optical slice thickness for the 
fluorochromes emitting at higher wavelengths. Three-dimensional 
projections  were  digitally  reconstructed  from  confocal  z-stacks. 
Colocalization of signals was assessed from single confocal optical 
sections. Images of whole retinas were acquired using tile scanning 
using a pinhole diameter greater than three Airy units.
Immunohistochemical Staining
Five-to seven-micrometer sections of paraffin-embedded tissue or 
frozen sections were immunostained with monoclonal antibodies 
against  platelet  endothelial  cell  adhesion  molecule  1[PECAM-1, 
also known as cluster of differentiation 31 (CD31); BD Biosciences, 
San Diego, CA; dilution 1:500], lymphatic vessel endothelial hyal-
uronan receptor-1 (LYVE-1) (29), neural/glial antigen 2 (NG-2; 
MAB5384; Millipore; dilution 1:300), or laminin (NeoMarkers, 
Fremont,  CA;  dilution  1:500).  The  occurrence  of  metastatic 
LNM35 foci in lymph nodes was detected using anti-cytokeratin 7 
antibodies (Millipore; dilution 1:200). The primary antibodies were 
detected with the Tyramide Signal Amplification detection method 
(PerkinElmer Life Sciences, Waltham, MA) according to manufac-
turer instructions or using fluorescently conjugated secondary anti-
bodies (Molecular Probes, Invitrogen; dilution 1:500 for 1 hour). 
Immunofluorescent  staining  to  detect  pimonidazole  adducts  was 
done with the HypoxyProbe-1 Plus Kit as instructed by the manu-
facturer (Natural Pharmacia International, Burlington, MA).
Cell Staining
All cells were fixed for 10 minutes in 4% paraformaldehyde (PFA) 
phosphate  buffered  saline  (PBS),  permeabilized  3  minutes  with   
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serum albumin (BSA) PBS, and incubated with primary antibodies 
against  Tie1  (dilution  1:100),  phosphorylated  Tie2  (dilution 
1:100), Tie2 (dilution 1:100) and Ang2 (dilution 1:50) (all from 
R&D Systems, Minneapolis, MN), VE-cadherin (BD Biosciences; 
dilution 1:100), phosphorylated endothelial nitric oxide synthase 
(pS1177; Cell Signaling Technology Inc, Danvers, MA; dilution 
1:50), or a tight junction marker ZO-1 (Invitrogen; dilution 1:200), 
in 1% BSA PBS 30 minutes at room temperature. The cells were 
then  incubated  with  secondary  antibodies  (Molecular  Probes, 
Invitrogen; dilutions 1:300) 30 minutes at room temperature. All 
experiments were repeated at least twice with similar results.
Endothelial–Tumor Cell Coculture
BECs transfected with Tie2-GFP (30) retrovirus were cultured on 
fibronectin-coated Transwell filters (0.4 mm pore size) overnight, 
after which the filters were transferred to new 24-well plates with 
or without overnight cultures of LNM35 in the lower compart-
ment (31). The cells were grown in endothelial cell medium for 
48 hours in the presence or absence of the Ang2-blocking antibody 
(2 µg/mL), after which BECs were fixed and used for immunoflu-
orescence staining.
Image Analysis
Bright field sections were viewed with a Leica DM LB microscope 
(Leica  Microsystems  GmbH,  Wetzlar,  Germany),  and  images 
were captured with a Penguin Pro 600es color camera (Pixera 
Corporation, Santa Clara, CA). Immunofluorescent images were 
captured with a Zeiss digital Axiocam camera connected to a 
Zeiss  Axioplan  2  microscope  (Carl  Zeiss  AG,  Oberkochen, 
Germany). Confocal images were captured using laser scanning 
confocal microscopes Zeiss LSM 510 Meta, Zeiss LSM 5 Duo 
(Carl Zeiss AG), and Olympus FluorView FV1000 (Olympus, 
Tokyo, Japan).
At least five tumors were examined in each experimental group, 
and images from three distinct areas characterized by the mean 
representative density of vessels were captured from each tumor 
under evaluation. The image quantification was carried out using 
ImageJ  software  (The  National  Institutes  of  Health,  Bethesda, 
MD).
Ang2 Small Interfering RNA (siRNA) Experiments
Sixty percent confluent overnight cultures of BECs expressing the 
previously  characterized  Tie2-GFP  retrovirus  vector  (24)  were 
transfected with siRNA targeted against human Ang2 (Santa Cruz, 
CA; sc-39305) or with control siRNA (Santa Cruz; sc-37007) using 
Oligofectamine (Invitrogen) and analyzed 48 hours later.
Analysis of Internalization of Cell Surface–Bound Anti-
Ang2 antibody
LECs  transfected  with  Tie2-GFP  lentivirus  were  incubated  in 
ECBM with anti-Ang2 antibody or control hIgG (2 µg/mL) on ice 
for 40 minutes following 30 minutes incubation on ice or at 37°C 
to induce the antibody uptake. Cells were either fixed with 4% 
PFA PBS or subjected to acid wash (2 mM glycine in Dulbecco, 
pH 2.0) for 15 minutes to remove the plasma membrane–bound 
antibodies and then fixed. For immunofluorescence staining, cells 
were permeabilized for 5 minutes with 0.1% Triton X-100 in PBS.
In Vitro Detection of Adenoviral Expression
To assess the expression of the adenoviral vector encoded constructs, 
HeLa cells were treated with DMEM starvation medium 30 minutes 
and  transfected  for  2  hours  with  adenoviruses  expressing  Ang2 
(AdAng2) or ß-galactosidase (AdLacZ) (100 MOI). The cells were 
incubated in complete DMEM for 2 days, starved for 40 minutes in 
methionine- and cysteine-free Eagle’s Minimum Essential Medium, 
and metabolically labeled in this medium supplemented with [35S]
methionine/[35S]cysteine (Amersham Biosciences and GE Healthcare, 
Waukesha, WI) at 100 µCi/mL for 10 hours. Conditioned medium 
was then harvested and cleared of particulate material by centrifu-
gation.  Proteins  were  immunoprecipitated  with  a  monoclonal 
antibody against the FLAG tag (Sigma-Aldrich; dilution 1:100) in 
the AdAng2 construct. The antigen–antibody complexes were in-
cubated with protein G sepharose (Amersham Biosciences), sub-
jected to sodium dodecyl sulfate–polyacrylamide (SDS–PAGE) gel 
electrophoresis and visualized with autoradiography.
Construction of Plasmids and Production of Recombinant 
Adeno-Associated Virus (AAV) Vectors
A  1965-bp  fragment  comprising  the  mouse  Tie2  extracellular 
domain  (mTie2-ECD)  coding  region  was  obtained  from  the 
mTEK plasmid (32), digested with EcoRI and BglII, and inserted 
into the pVK1 plasmid. The DNA fragment coding for a VSV tag 
was synthesized, digested with BglII and MluI, and inserted into 
the mTie2-ECD construct, followed by introduction of the Kozak 
consensus  sequence  (33).  The  mTie2-ECD-VSV  fragment  was 
then inserted into a psubCMV-WPRE rAAV expression vector 
(34). A plasmid coding for mouse Tie2-ECD fused to a FLAG tag 
was also constructed. The fragment coding for a FLAG sequence 
was synthesized, digested with BglII and MluI, and inserted into 
the  mTie2-ECD-psubCMV-WPRE  plasmid.  The  recombinant 
AAVs of serotype 9 were produced as described previously (35), 
with the exception that the helper plasmid p5E18-VP2/9 was used 
instead of p5E18-VP2/8 (36). The primer sequences and plasmid 
constructs are represented in Supplementary Tables 1 and 3 (avail-
able online).
Confirmation of AAV Expression by Immunoprecipitation 
and Immunoblotting
AAV9-sTie2-ECD-FLAG or AAV9-sTie2-ECD-VSV vector, or 
AAV-HSA  as  a  negative  control,  was  injected  into  the  tibialis   
anterior muscles of 6- to 8-week-old C57Bl/6 mice (n = 5 in each 
group, at the dose of 5 × 10
11 to 1 × 10
12 virus particles [vp] per 
mouse)  anesthetized  with  the  mixture  of  Ketalar  (Pfizer)  and 
Rompun vet (Bayer Healthcare). Expression of the soluble form   
of Tie2 was confirmed in blood samples taken 2 weeks after the 
injections. For this, 10-µL samples of serum from each mouse of 
the same group was pooled and incubated with anti-VSV or anti-
FLAG antibodies (Sigma-Aldrich). Proteins were immunoprecipi-
tated with protein G sepharose (Amersham Biosciences), followed 
by separation by 10% SDS–PAGE, and transferred to a nitrocel-
lulose membrane. The membrane was incubated with anti-Tie2 
antibodies (R&D Systems), biotinylated anti-goat secondary anti-
body (Dako, Glostrup, Denmark; dilution 1:2500 for 30 minutes), 
followed by streptavidin–biotin horseradish peroxidase conjugate 
(Amersham  Biosciences;  dilution  1:8000  for  20  minutes).  The jnci.oxfordjournals.org    JNCI | Articles 465
Figure 1. Effect of Ang2 on LNM35 primary tumor growth and vascu-
larization. A) Representative images and quantification of biolumines-
cence of LNM35 tumors in AdAng2- and AdLacZ-treated mice at 14 
days  after  implantation,  AdAng2  (n  =  10)  vs  AdLacZ  (n  =  9)  mice. 
Student’s  t  test.  B)  Growth  curves  of  the  tumors  in  (A).  Repeated 
measures one-way analysis of variance. C and D) Representative im-
munohistochemical images of CD31- and LYVE-1-stained tumor sec-
tions.  Samples  from  at  least  five  mice  from  both  groups  were 
quantified.  Quantification  of  CD31-  and  LYVE-1-positive  vessel  den-
sities. Student’s t test. Error bars = 95% confidence intervals. Scale bar 
in (A), 10 mm; in (C and D), 200 µm. *P < .05. All statistical tests were 
two-sided. Ang2 = Angiopoietin-2; CD31 = cluster of differentiation 31; 
LacZ = b-galactosidase; LYVE-1 = lymphatic vessel endothelial hyaluro-
nan receptor-1; p/s/cm2/sr = photons/s/cm2/steradian.
proteins were then detected by enhanced chemiluminescence by 
using the SuperSignal West Femto Maximum Sensitivity Substrate 
kit (Thermo Scientific, Rockford, IL).
In Vivo Tumor Assays Using Recombinant AAVs
AAV9-sTie2-ECD  or  AAV9-HSA  was  injected  intravenously 
into  the  lateral  tail  vein  of  6-  to  8-week-old  female  nu/nu 
BALB/c mice (n = 14 in both groups) at a dose of 5 × 10
11 to 
1 × 10
12 vp per mouse, 3 weeks before implantation of LNM35 
cells. The expression of the soluble form of Tie2 was confirmed 
as described above. LNM35 cells were then implanted subcuta-
neously  into  both  abdominal  flanks  of  the  mice.  Once  the 
tumors  became  readily  detectable  during  the  first  few  days, 
tumor growth was monitored every second day with measure-
ments using a digital caliper, and the volumes were calculated as 
described  below.  For  labeling  of  hypoxic  regions  within  the 
tumors,  pimonidazole  (60  mg/kg;  Natural  Pharmacia 
International,  Burlington,  MA)  was  injected  intravenously 
under  anesthesia  1  hour  before  killing.  At  the  endpoint,  the 
mice  were  killed  and  tumors  were  excised  and  processed  for 
histology.
Statistical Analysis
Statistical analysis was performed with the unpaired t test. Fisher 
exact test was used for the statistical analysis of metastasis occurrence 
and repeated measures one-way analysis of variance was used for 
the analysis of primary tumor growth curves. All statistical tests 
were two-sided. The values are expressed as means ± 95% confi-
dence interval (CI) in the figures, and as means with the difference 
of means and 95% confidence intervals in the text. Differences 
were considered statistically significant at P less than .05.
Results
The Effect of Ang2 Overexpression on Metastasis of Human 
Lung Carcinoma Xenografts
AdAng2 promoted primary LNM35 human lung carcinoma tumor 
growth when compared with AdLacZ. This increased growth was 
observed as enhanced bioluminescence of the tumors in AdAng2-
transfected mice (AdAng2 [n = 10] vs AdLacZ [n = 9] mice: 25.46 × 105 
vs 10.61 × 105 photons/s/cm2/sr; difference = 14.85 × 105 photons/
s/cm
2/sr, 95% CI = 6.51 × 10
5 to 23.19 × 10
5 photons/s/cm
2/sr, 
P = .002; Figure 1, A) and as an increase in tumor volume (AdAng2 466   Articles | JNCI  Vol. 104, Issue 6  | March 21, 2012
[n = 10] vs AdLacZ [n = 9] mice: 797 vs 528 mm
3 at day 14; difference = 
269 mm
3, 95% CI = 170 to 371 mm
3, n = 9, P < .001; Figure 1, B). 
AdAng2  expression  was  also  associated  with  an  increase  in  the 
density of tumor blood vessels (AdAng2 [n = 5] vs AdLacZ [n = 6] 
mice: 68.43 vs 48.85 vessels per grid; difference = 19.58 vessels per 
grid, 95% CI = 0.09 to 39.07 vessels per grid, P = .049; Figure 1, C) 
and lymphatic vessels (AdAng2 [n = 5] vs AdLacZ [n = 6] mice: 18.13 
vs 12.67 vessels per grid; difference = 5.46 vessels per grid, 95%   
CI = 1.11 to 9.81 vessels per grid, P = .019; Figure 1, D). Importantly, 
AdAng2 increased regional lymph node metastasis when measured   
3 weeks after subcutaneous implantation of LNM35 tumor cells 
(Figure 2, A and D, and data not shown, a trend for increased 
bioluminescent signal intensity from lymph nodes in AdAng2 mice 
ex  vivo,  AdAng2  vs  AdLacZ  mice:  6.36  ×  10
7  vs  1.02  ×  10
7 
Figure 2. Effect of Ang2 expression on lung 
metastasis. A) Representative biolumines-
cent  images  of  inguinal  lymph  nodes  3 
weeks  after  subcutaneous  implantation  of 
LNM35  tumors.  B)  Representative  ex  vivo 
bioluminescent images of lungs at 7 weeks 
after  implantation  of  luciferase-positive 
LNM35  cells  into  the  abdominal  subcutis   
(4 weeks after the excision of the primary 
tumor). C) Representative images of hema-
toxylin-  and  eosin-stained  lung  sections 
from  AdAng2-  and  AdLacZ-treated  mice 
killed 3 weeks after systemic LNM35 inocu-
lation. D) analysis of lymph node volumes, 
represented  in  (A),  AdAng2  (n  =  10)  vs 
AdLacZ (n = 9) mice. E) Analysis of LNM35 
metastatic foci per grid in histological sec-
tions from the experiment in (C), n = 4 in 
both  groups.  F)  Quantification  of  lung 
weights 7 weeks after s.c. tumor cell implan-
tation of LNM35 cells and 3 weeks after i.v. 
of the tumor cells, AdAng2 (n = 3) vs AdLacZ 
(n = 6) mice and n = 4 in both groups, respec-
tively. G) Representative lungs with B16-F10 
metastases  in  AdAng2-  vs  AdLacZ-treated 
mice at 2 weeks after intravenous adminis-
tration  of  tumor  cells.  H)  Bioluminescent 
images of lungs with B16-F10 metastatic foci. 
I and J) Analysis of B16-F10 lung metastasis 
foci  per  grid  (AdAng2  vs  AdLacZ)  and   
lung  weights,  n  =  4  in  both  groups.  K) 
Quantification of B16-F10 melanoma tumor 
burden  in  conditionally  transgenic  Ang2 
mice (VEC-tTA/Tet-OS-Ang2 mice) and con-
trols,  VEC-tTA/Tet-OS-Ang2  mice  [n  =  5], 
and control [n = 4] mice. All statistical tests 
were two-sided Student’s t tests. Asterisks 
indicate statistically significant differences. 
Error bars = 95% confidence intervals. Scale 
bar in (A) and (G), 2 mm; in (B), 5 mm; in (C), 
1  mm  (left  panel);  100  µm  (right  panel). 
Ang2 = Angiopoietin-2; LacZ = b-galactosidase; 
i.v.  =  intravenous;  s.c.  =  subcutaneous;  
p/s/cm
2/sr  =  photons/s/cm
2/steradian;  VEC-
tTA/Tet-OS-Ang2  =  VE-cadherin-tTA/Tet-OS-
Ang2 transgenic mouse.jnci.oxfordjournals.org    JNCI | Articles 467
photons/s/cm
2/sr), reflected as a statistically significant increase of 
inguinal lymph node volume in AdAng2-treated mice (AdAng2 [n = 
10] vs AdLacZ [n = 9] mice: 19.82 vs 5.96 mm
3; difference = 13.86 
mm
3, 95% CI = 2.24 to 25.49 mm
3, P = .022; Figure 2, D).
AdAng2 also promoted metastasis of the LNM35 tumor cells 
into the lungs, as indicated by a statistically significant increase in 
lung weight (AdAng2 [n = 3] vs AdLacZ [n = 6] mice: 0.59 vs 0.28 g:   
difference = 0.31 g, 95% CI = 0.05 to 0.57 g, P = .027; Figure 2, F), 
and a trend for increased bioluminescence signal in the lungs of 
AdAng2 expressing vs control mice (AdAng2 2.45 × 10
7 vs AdLacZ 
0.33  ×  10
7  photons/s/cm
2/sr;  Figure  2,  B),  both  measured  at 
4 weeks after the excision of the primary tumor. Furthermore, Ang2 
enhanced the establishment and growth of tumor cell colonies in 
the lungs at 3 weeks after the intravenous injection of LNM35 cells 
into immunodeficient NSG mice as evaluated by the lung weight 
(AdAng2 vs AdLacZ mice: 0.64 vs 0.42 g: difference = 0.21 g, 95% 
CI = 0.04 to 0.38 g, P = .02; Figure 2, F) and the density of metas-
tastic foci in lungs (AdAng2 [n = 4] vs AdLacZ [n = 4] samples: 15.6 
vs 9.7 metastatic foci per grid; difference = 6.1, 95% CI = 2.8 to 9.3, 
P = .004; Figure 2, C and E). Similar results were obtained when 
B16-F10 melanoma cells were used (Figure 2, G–J, metastatic foci 
per grid in lungs of AdAng2- vs AdLacZ-treated mice [n = 4 in 
both groups]: 47.1 vs 20.4; difference = 26.6, 95% CI = 11.2 to 
42.1, P = .006; Figure 2, I).
Expression of Ang2 is induced in the endothelium of hypoxic 
tumor vessels (15). We analyzed the effect of endothelial Ang2 
overexpression on tumor cell metastasis in a conditionally Ang2-
overexpressing  transgenic  mouse  model  (VEC-tTA/Tet-OS-
Ang2),  in  which  the  VE-cadherin-tTA  construct  drives  Ang2 
expression after the discontinuation of tetracycline administration. 
Isogenic B16-F10 cells were injected into the tail vein of Ang2-
overexpressing mice, and their littermate controls and the lungs 
were collected 3 weeks after injections. The total lung colony bur-
den was statistically significantly increased in Ang2-overexpressing 
mice when compared with the controls (VEC-tTA/Tet-OS-Ang2 
[n = 5] vs control [n = 4] mice: 45.23 vs 12.26 mm
2; difference 32.67 
mm
2, 95 % CI = 31.87 to 34.07, P < .001; Figure 2, K).
The Effect of Ang2-Blocking Antibody on Inhibition of 
Lymphatic and Lung Metastasis
To assess the role of endogenous Ang2 produced by endothelial 
cells of tumor vessels, we used an Ang2-blocking antibody (27). 
Luciferase-tagged LNM35 cells were implanted subcutaneously into 
nu/nu and SCID mice, and after tumor establishment, the mice were 
randomly assigned to receive 10 mg/kg doses of Ang2-blocking 
antibody or control hIgG every other day. The Ang2-blocking 
antibody statistically significantly inhibited primary tumor growth 
(Figure 3, A and B, tumor weight at excision in nu/nu mice: in 
Ang2-blocking vs in hIgG group, n = 8 for both groups, 0.84 vs 
1.36 g; difference = 0.52 g, 95% CI = 0.81 to 0.23 g, P = .002; in 
SCID mice: in Ang2-blocking group vs in hIgG control mice, n = 10 
in both groups, 0.81 vs 1.09 g; difference = 0.28 g, 95 % CI = 0.003 
to 0.54 g, P = .048) as well as tumor angiogenesis (Ang2-blocking 
antibody vs hIgG group, n = 8 in both groups, 17.85 vs 21.45   
CD31-positive vessels/grid; difference = 3.60, 95% CI = 0.70 to 
6.50, P = .019; Figure 3, C and D and Supplementary Figure 1, 
available online), as expected on the basis of previously published data 
Figure 3. Ang2-blocking antibodies inhibit primary tumor growth, an-
giogenesis, and lymphangiogenesis. A) Growth curves of LNM35 primary 
tumors in nu/nu mice treated with the Ang2-blocking antibodies or hIgG 
control, n = 8 in both groups. One-way analysis of variance. B) Tumor 
weights at excision 16 days after implantation, P = .002. Student’s t test. C) 
Representative  immunohistochemical  images  of  LYVE-1-  and  CD31-
stained tumor sections. D) Quantification of densities and area fractions of 
Lyve-1-positive lymphatic vessels and of CD31-positive blood vessels from 
at least five histological sections, P = .013 and .019, respectively. Student’s 
t test. All statistical tests were two-sided. *P < .05. Error bars = 95% CI. 
Anti-Ang2 = angiopoietin-2-blocking antibody; CD31 = cluster of differenti-
ation 31; hIgG = human immunoglobulin G; LYVE-1 = lymphatic vessel 
endothelial hyaluronan receptor-1. Scale bar, 120 µm.468   Articles | JNCI  Vol. 104, Issue 6  | March 21, 2012
using Ang2-blocking antibodies in various tumor xenografts (16,19). 
The Ang2-blocking antibody appeared to induce regression of the 
endothelium, whereas pericytes and basement membrane structures 
were  detected  even  after  anti-Ang2  antibody  treatment 
(Supplementary Figure 2, available online). Importantly, the Ang2-
blocking antibody also attenuated tumor lymphangiogenesis (Ang2-
blocking group vs hIgG control group, n = 8 in both groups, 11.95 vs 
15.37 LYVE-1-positive vessels per grid; difference = 3.42, 95% CI = 
0.85 to 5.98, P = .013; Figure 3, C and D).
Similar to the Ang2-blocking antibodies, administration of the 
extracellular domain of Tie2 that binds both Ang1 and Ang2 via an 
AAV vector resulted in an inhibition of LNM35 tumor growth and 
angiogenesis (Supplementary Figure 3, available online), consis-
tently with the previously reported results (37).
To analyze the effect of Ang2-blocking antibodies on tumor 
metastasis, we measured tumor cell dissemination into the regional 
(inguinal) lymph nodes. The rate of lymph node metastasis and 
lymph node weight at the time of excision of primary tumors were 
decreased  in  SCID  mice  treated  with  the  Ang2-blocking  anti-
bodies (10% in the anti–Ang2-treated group vs 70% in control 
hIgG group) (Figure 4, A–C, lymph node weight: P = .020 [SCID, 
lower panel, Figure 4, C] to P = .043 [nu/nu, upper panel, Figure 4, 
C]). There was a clear trend of inhibition of the metastatic dissem-
ination of tumor cells into axillary lymph nodes of SCID mice as 
evaluated by the occurrence of metastasis (data not shown, 0/10 in 
Ang2-blocking group vs 4/10 in hIgG group) and the occurrence 
of cytokeratin-positive cells (Figure 4, D).
To evaluate whether Ang2 blockade affected homing of tumor 
cells into the lungs, luciferase-tagged LNM35 cells were injected 
intravenously into mice receiving the Ang-blocking antibody or 
hIgG and analyzed by the bioluminescent signal intensity from the 
excised  lungs  at  5  days.  The  anti-Ang2  antibody  treatment 
decreased the metastatic burden in the lungs (Ang2-blocking anti-
body  vs  hIgG:  103.4  vs  225.6  photons/s/cm
2/sr,  n  =  3  in  both 
groups, two independent studies, difference = 122.2, 95% CI = 
38.4 to 206.0, P = .016; Figure 5, A and B). The metastatic foci in 
the lungs were also analyzed at 8 days after systemic inoculation of 
GFP-tagged tumor cells. The Ang2-blocking antibody inhibited 
lung metastasis formation statistically significantly (Ang2-blocking 
antibody [n = 4] vs hIgG [n = 3], 12.2 vs 22.4 LNM35 cell clusters 
per grid; difference = 10.2, 95% CI = 5.6 to 14.9, P = .002; Figure 
5, C and E). The inhibition of LNM35 lung metastasis by the 
Ang2-blocking antibody was also evident at the later time point of   
2 weeks (tumor area per grid in Ang2-blocking antibody vs hIgG 
groups, n = 4 in both groups: 14.78% vs 24.33%; difference = 9.55, 
95% CI = 3.12 to 15.98, P = .011; Figure 5, H left; and lung 
weight: Ang2-blocking antibody vs hIgG 0.22 vs 0.27 g, difference 
= 0.05 g, 95% CI = 0.01 to 0.09 g, P = .017, Figure 5, H right). In 
contrast, overexpression of Ang2 promoted tumor metastasis into 
the  lungs  when  analyzed  4  days  after  inoculation  of  the  GFP-
tagged LNM35 or LLC tumor cells (LLC cell cluster density in 
AdAng2 vs AdLacZ group, n = 4 in both groups, 35.7 vs 28.9, 
difference = 6.8, 95% CI = 1.7 to 12.0, P = .018; LNM35 cell clus-
ter density in AdAng2 vs AdLacZ group, n = 4 in both groups, 6.17 
Figure  4.  Ang2-blocking  antibodies  inhibit  lymphatic  metastasis.  A) 
Representative ex vivo bioluminescent images of the regional inguinal lymph 
nodes in nu/nu and SCID mice, excised at 16 days after subcutaneous tumor 
implantation, n = 8 and n = 10 in both groups, respectively. B) Quantification of 
bioluminescence  emission  from  the  regional  lymph  nodes.  C)  Occurrence 
of metastasis in regional lymph nodes, and lymph node weights, P = .020 to 
P = .043. D) Representative images of intranodal cytokeratin 7–positive immu-
nostaining in axillary lymph nodes excised from Ang2-blocking antibody and 
hIgG-treated  nu/nu  mice.  Error  bars  =  95%  confidence  intervals. 
*P  <  .05.  Anti-Ang2  =  angiopoietin-2-blocking  antibody;  hIgG  =  human 
immunoglobulin G; p/s/cm2/sr = photons/s/cm2/steradian. Student’s t test. All 
statistical tests were two-sided. Scale bar in (A), 2 mm, in (D), 40 µm.jnci.oxfordjournals.org    JNCI | Articles 469
Figure 5. Ang2 overexpression induces and Ang2-blocking antibodies 
suppress  formation  of  metastatic  foci  in  lungs.  A)  Bioluminescent 
images of lungs from Ang2-blocking antibody and hIgG control–treated 
NSG  mice  5  days  after  systemic  inoculation  of  luciferase- 
positive LNM35 cells. Two independent studies with similar results. B) 
Quantification  of  bioluminescent  signal  intensities,  n  =  3  in  both 
groups, P = .016. C and D) Representative fluorescent micrographs of 
lung sections with foci of GFP-positive LNM35 metastatic cells at 8 days 
after intravenous inoculation of the cells into Ang2-blocking antibody 
vs hIgG-treated mice (C), and at 4 days after systemic inoculation into 
the tail vein of mice treated with AdAng2 or AdLacZ (D). E) Analysis of 
GFP-positive LNM35 foci and GFP signal area fraction in lung tissues of 
mice treated with Ang2-blocking antibodies or hIgG control, n = 4 in 
anti-Ang2 antibody group, n =3 in hIgG group. F) Quantification of the 
homing of intravenously injected GFP-positive LLC and LNM35 tumor 
cells into the lungs of AdAng2- or AdLacZ-treated mice, n = 4 in both 
groups,  P  =  .019.  G)  Representative  HE-stained  lung  sections  with 
LNM35 metastatic foci analyzed 2 weeks after intravenous inoculation 
of  the  tumor  cells  to  mice  treated  with  Ang2-blocking  antibodies  vs 
hIgG. H) Quantification of metastatic area fraction in HE-stained sections 
and lung weights at excision, P = .028. Error bars = 95% confidence 
intervals. Scale bar in (A), 15 mm. Anti-Ang2 = angiopoietin-2-blocking 
antibody; GFP = green fluorescent protein; hIgG = human immunoglob-
ulin G; NSG = NOD SCID gamma; p = photons; p/s/cm
2/sr = photons/
s/cm
2/steradian. *P < .05. Student’s t test. All statistical tests were 
two-sided.
vs 2.67, difference = 3.50, 95% CI = 0.81 to 6.19, P = .019; Figure 
5, D and F).
Effects of Endothelial Ang2 Overexpression and Ang2-
Blocking Antibody on Vascular Integrity in Lung 
Metastases
To explain the effects of Ang2 overexpression and Ang2-blocking 
antibody on lung metastasis, we investigated their effects on the 
ultrastructure  of  the  endothelial  barrier.  Endothelial  cell–cell 
junctions and cell adhesion to the underlying basement membrane 
were analyzed by transmission electron microscopy in metastasis-
associated blood capillaries in the lung colonization assay in condi-
tional Ang2-overexpressing, Ang2-blocking antibody-treated and 
control mice. The metastasis-associated capillaries in the Ang2-
overexpressing mice showed more frequent and profound alter-
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(percent of analyzed capillaries, Ang2-overexpressing [n = 132] vs 
control mice [n = 130]: 66.5% vs 20.2%). These abnormalities in-
cluded endothelial cell detachment from the basement membrane 
(Ang2-overexpressing vs control mice: 49.6% vs 12.2%) and less 
extensive endothelial cell–cell junctions or even gaps between the 
endothelial cells (24.3% vs 8.1%) (Figure 6, A–D). The Ang2-
blocking antibodies reduced endothelial cell swelling and hetero-
geneity of metastasis-associated capillaries in the NSG mice and 
showed  more  prominent  endothelial  adherens  junctions  when 
compared with capillaries adjacent to the metastases in HSA con-
trol mice (Figure 6, E–H and Supplementary Figure 4, available 
online).
Influence of Ang2-Blocking Antibody on Postnatal Retinal 
Angiogenesis
Neonatal  retinal  angiogenesis  is  dependent  on  Ang2  expression 
(12), and blocking Ang2 has been found to inhibit retinal angiogen-
esis (27). To further investigate the role of Ang2 during physiolog-
ical  retinal  angiogenesis,  we  injected  Ang2-blocking  or  control 
antibodies to newborn NMRI pups during postnatal days P0–P4. 
In  line  with  results  from  a  parallel  independent  study  (27),  we 
observed a statistically significant decrease in retinal vascularization 
in the Ang2-blocking antibody-treated pups when compared with 
the control group. In addition, we found decreased branching den-
sity (Supplementary Figure 5, A and B, available online) and vascu-
lar tuft-like structures located at the edge of the advancing vessel 
network (Supplementary Figure 5, A, available online) in the Ang2-
blocking antibody-treated pups Tie2 was expressed in the retinal 
vessels, except for the tip cells. However, reduced Tie2 staining was 
detected  in  the  angiogenic  front  of  anti-Ang2  antibody  treated 
pups, whereas the expression of the receptor in the rest of the retina 
was  not  altered  (Supplementary  Figure  5,  C,  available  online). 
High-resolution imaging of the retinas treated with Ang2-blocking 
antibody revealed isolated patterns of pericytes that were not asso-
ciated with endothelial cells (Supplementary Figure 5, D and E, 
available online), suggestive of vessel regression or failed sprouts.
The Effect of Blocking Ang2 Antibodies on Ligand-Induced 
Cellular Trafficking of the Tie2 Receptor
To study the cellular mechanisms responsible for the in vivo effects 
of the Ang2-blocking antibody, we analyzed its effects on cultured 
microvascular endothelial cells. Our previous results (30) and those 
of Fukuhara et al. (38) have recently shown that Ang1 induces a 
distinct Tie2 signaling complex at endothelial cell–cell contacts, 
where it provides survival and stability signals and induces phos-
phorylation  of  the  endothelial  nitric  oxide  synthetase  (eNOS) 
(30,38). In the previous report, Ang2 was found to compete with 
Ang1 for receptor binding at the cell–cell junctions (30). To eluci-
date the effects of the Ang2-blocking antibodies on this process, 
endothelial cells expressing Tie2 fluorescently tagged with GFP 
were treated with the Ang2-blocking or control antibodies. In mi-
crovascular lymphatic and blood vascular endothelial cells, which 
produce Ang2 in culture (39), Tie2 and Ang2 were localized at the 
cell–cell junctions (Figure 7, A and B). However, autocrine Ang2 
induced  only  weak  Tie2  phosphorylation  and  almost  no  eNOS 
phosphorylation when compared with exogenously provided Ang1 
(Figure 7, A, Supplementary Figure 6, A, available online).
Figure  6.  Effect  of  Ang2-blocking  antibodies  on  endothelial  cell–cell 
junctions in lung metastases and Ang2 overexpression on vascular integ-
rity. Transmission electron micrographs (TEM) of capillaries adjacent to 
metastatic B16-F10 melanoma cell (MC) colonies of Ang2-overexpressing 
(A and B) and control C57Bl/6J mice (C and D). TEM micrographs of 
Ang2-blocking antibody (E and F) and HSA-treated (G and H) metastases 
of NSG mice, samples from at least three mice were evaluated. (B), (D), 
(F), and (H) show the boxed areas at a higher magnification. Note that in 
the  Ang2-overexpressing  mice,  the  capillaries  show  more  structural   
abnormalities in endothelial cell (EC), basement membrane (BM) adhe-
sions and less extensive endothelial cell–cell junctions (arrows in B and 
D) than in the control mice. Arrowheads in (B) and (D) indicate the 
interface between the ECs and the BM. Note also that the Ang2-blocking 
antibody treatment has a normalizing effect; the endothelium in the   
HSA-treated  lung  metastasis  has  less  prominent  (stars)  junctional 
complexes (arrows) and uneven EC layering. Scale bar in (A), (C), (E), 
and (G), 1 µm; in (B), (D), (F), and (H), 500 nm. Anti-Ang2 = angiopoietin-
2-blocking antibody; HSA = human serum albumin; NSG = NOD SCID 
gamma; RBC = red blood cell; VEC-tTA/Tet-OS-Ang2 = VE-cadherin-tTA/
Tet-OS-Ang2 transgenic mouse.jnci.oxfordjournals.org    JNCI | Articles 471
The Ang2-blocking antibody induced internalization of Ang2, 
leading to decreased Tie2 and Tie1 receptor localization and Tie2 
phosphorylation at the endothelial cell–cell contacts (Figures 7, A 
and B and 8 and Supplementary Figure 7, available online). In 
contrast,  the  Ang2-blocking  antibody  did  not  inhibit  Ang1-
stimulated Tie2 localization and phosphorylation at cell–cell contacts, 
indicating specific blockade of only the Ang2 signals (Figure 7, A). 
Internalized vesicles containing Ang2 were observed at 30 minutes 
of  treatment  with  Ang2-blocking  antibodies,  but  after  5  hours, 
they were no longer visible (Figure 8). Decreased formation of 
Figure 7. Ang2-blocking antibody inhibits the formation of Ang2-induced 
Tie2 signaling complexes. A) Human dermal microvascular lymphatic 
endothelial cells (LECs) were transfected with the Tie2-GFP retrovirus. 
The cells were treated with Ang2-blocking antibody (48 hours) or left 
untreated, followed by stimulation with COMP-Ang1 (30 minutes). The 
cells were fixed, permeabilized, and stained for Ang2 and phosphory-
lated Tie2 (P-Tie2). Note that the Ang2-blocking antibody inhibits Tie2 
translocation induced by endogenous Ang2 but not by exogenous 
COMP-Ang1 added to the cultures. B) Blood vascular endothelial cells 
(BECs)  were  transfected  with  Tie2-GFP  and  treated  for  30  minutes  
with Ang2-blocking antibody or hIgG as a control. The cells were fixed, 
permeabilized, and stained for VE-cadherin or Ang2. The Ang2-blocking 
antibody  inhibits  Ang2-induced  Tie2  translocation  also  in  the  BECs. 
Nuclear DAPI stain. Confocal images. Scale bar, 20 µm. Anti-Ang2 = 
angiopoietin-2-blocking  antibody;  COMP-Ang1  =  cartilage  oligomeric 
matrix protein–angiopoietin-1; hIgG = human immunoglobulin G.472   Articles | JNCI  Vol. 104, Issue 6  | March 21, 2012
Figure 8. Ang2-blocking antibody induces internalization of the Ang2-
Tie2  complexes.  BECs  transfected  with  Tie2-GFP  retrovirus  were 
treated with Ang2-blocking or hIgG control antibody for the indicated 
periods. The cells were fixed, permeabilized, and stained for Ang2. 
Note  that  the  Ang2-blocking  antibody,  but  not  control  antibody,   
induces  transient  internalization  of  Ang2  and  Tie2  in  intracellular 
vesicles, evident at 30 minutes, whereas no vesicles are present at   
5 hours after Ang2-blocking antibody treatment. Nuclear DAPI stain. 
Confocal images. Scale bar, 20 µm. Ang2 = Angiopoietin-2-detecting 
antibody;  Anti-Ang2  =  angiopoietin-2-blocking  antibody;  BEC  = 
blood microvascular endothelial cells; hIgG = human immunoglob-
ulin G.
Ang2-Tie2 complexes was also detected following transfection of 
Tie2-GFP expressing cells with siRNA oligonucleotides to silence 
Ang2 expression (Supplementary Figure 6, B, available online).
We further analyzed the internalization of cell surface–bound 
anti-Ang2  antibody  in  LECs.  To  this  end,  the  anti-Ang2  anti-
bodies were incubated with cells on ice and either directly sub-
jected to glycine wash for depletion of the cell surface or incubated 
at 37°C to allow internalization of cell surface bound antibodies. 
The acid wash completely removed cell surface–bound antibodies 
(0% remained from maximal binding), but the internalized anti-
bodies were retained in the cells (11% remained from maximal 
binding, Supplementary Figure 8, available online). These data 
indicate that the anti-Ang2 antibody is partially internalized into 
LECs in vitro.
To  investigate  the  effect  of  tumor  cells  on  Ang2-induced 
Tie2 signaling, we cultured Tie2-GFP expressing blood vascu-
lar  endothelial  cells  on  Transwell  filters  in  the  presence  or 
absence of the LNM35 lung carcinoma cells in the lower com-
partment. Notably, Ang2-Tie2 complexes were increased in the 
endothelial cell junctions in the presence of the LNM35 tumor 
cells,  whereas  complex  formation  was  blocked  by  the  Ang2-
blocking antibodies (Supplementary Figure 9, available online). 
These  results  suggest  that  the  Ang2-blocking  antibodies  are 
associated with decreased expression of Ang2-Tie2 complexes 
while leaving Ang1-Tie2 complexes intact at endothelial cell–
cell junctions.
Discussion
Our results indicate that Ang2 increases tumor metastasis at least 
in part by promoting endothelial disruption and increasing tumor 
cell translocation and homing to target organs. We also provide 
mechanistic  insight  into  the  effects  of  the  antibody-mediated 
blockade of Ang2 at the cellular level. To address the function of 
Ang2 in tumor metastasis, we used systemic and endothelial cell-
specific Ang2 overexpression, as well as Ang2-blocking antibodies 
in various tumor models. Our results demonstrate that systemic 
Ang2 overexpression promotes tumor lymphangiogenesis as well 
as lymph node and lung metastasis in addition to tumor growth 
and angiogenesis. Ang2 also enhanced the establishment of meta-
static colonies in the lungs after intravenous tumor cell inocula-
tion.  Importantly,  by  using  VEC-tTA/Tet-OS-Ang2  transgenic 
mice, in which Ang2 is specifically induced only in the vascular 
endothelium, we demonstrated that endothelial overexpression of 
Ang2 increases lung metastasis. Alternatively, Ang2 blockade atten-
uated tumor lymphangiogenesis, dissemination of tumor cells via 
the lymphatic vessels, lung metastasis, and tumor cell colonization 
of the lungs.
The antiangiogenic effects of specific Ang2 blockade on tumor 
growth  and  vascularization  have  been  previously  characterized 
using Ang2 blocking in various tumor xenografts, but the effects 
on tumor metastasis were not investigated (16,18,19,27). In one 
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RNA in mice bearing mammary tumor xenografts was reported to 
inhibition endothelial permeability in the lungs (40). In another 
report, Ang2 overexpression in tumor cells increased their invasive 
properties by an autocrine, Tie2-independent effect mediated via 
the integrins (9). However, only a minor fraction of human tumor 
cell lines express detectable amounts of Ang2 (1). Importantly, the 
lung cancer cells we used expressed no detectable Ang2 in culture, 
unlike  in  previous  studies  in  which  Ang2  inhibitors  were  used 
(16,41).
Targeted deletion of Ang2 leads to defective blood vessel develop-
ment in the eye and lymphatic vessel development in the mesente-
rium  and  skin  (12).  In  the  developing  postnatal  retina,  the 
Ang2-blocking  antibody  was  found  to  delay  vascularization  (27), 
which  was  confirmed  in  our  study.  Further  analysis  showed  that 
blocking Ang2 induced vascular tuft-like structures at the angiogenic 
front, where signs of sporadic sprout regression were observed. In the 
primary tumors treated with the Ang2-blocking antibody, basement 
membrane and pericyte marker–positive and endothelial cell negative 
vessel structures were present, similarly indicating endothelial regres-
sion. These results are consistent with the data that autocrine Ang2 
contributes to endothelial cell survival and migration in some con-
texts (10,42, our unpublished results using Ang2-blocking antibody). 
In mice surviving Ang2 deletion, an initial delay was observed in the 
growth of isogenic tumors (17); however, in our study, the Ang2-
blocking antibodies also induced statistically significant inhibition in 
the later phases of tumor growth. Thus, it is possible that genetic 
deletion of Ang2 and blocking antibodies against Ang2 have different 
mechanisms of action.
We (30) and Fukuhara et al. (38) have previously shown that 
angiopoietins  induce  the  formation  of  unique  Tie2  receptor 
complexes  in  endothelial  cells  (30,38).  In  cells  with  established 
contacts to other cells, Ang1 and Ang2 were found to trigger Tie2 
translocation to cell–cell junctions, where Ang1 has been shown to 
reduce paracellular permeability (30,38,43). Here, we show that 
autocrine Ang2 secreted by endothelial cells similarly induces Tie2 
and Tie1 translocation to cell–cell contacts. However, in contrast 
to Ang1, Ang2 induced only weak Tie2 phosphorylation and may 
thus decrease Ang1 signals via the Tie receptors in the endothelial 
cell–cell junctions (30). When the endothelial cells were cocul-
tured with the tumor cells, the presence of Ang2-Tie2 complexes 
was increased in the endothelial cell–cell junctions, even when the 
cells  were  under  normal  oxygen  pressure.  The  Ang2-blocking 
antibody inhibited endothelial Ang2 function by inducing the in-
ternalization of the Ang2-Tie2 receptor complexes and by inhibit-
ing the subsequent formation of such complexes. Because of the 
multimeric nature of Ang2, the anti-Ang2 antibody may result in 
the formation of large receptor clusters on the cell surface; these 
could  be  more  effectively  targeted  for  endocytosis.  The  Ang1-
induced Tie receptor complexes were not affected by the Ang2 
antibody.  Because  only  the  Ang2-bound  Tie2  receptor  fraction 
was  directed  for  internalization,  the  results  suggest  that  during 
Ang2 blocking in the metastatic lungs, Ang1 can bind and activate 
Tie2, contributing to stabilization of endothelial cell–cell junctions.
Our results showed that fewer tumor cell colonies were established 
in the lungs of mice treated with the Ang2-blocking antibody when 
compared  with  control  antibody–treated  mice  at  the  relatively 
early time points when angiogenesis was not yet detected in the 
metastatic foci. Although we have not imaged extravasation per se, 
these results suggest that blocking Ang2 inhibited the extravasa-
tion of tumor cells to the lungs or the very early stages of meta-
static  colony  establishment.  It  was  previously  shown  that  the 
tumor cell–associated lung capillaries express increased amounts of 
Ang2  (15).  In  the  pulmonary  vessels  associated  with  the  lung 
metastases, the Ang2-blocking antibody seemed to counteract the 
disruption of the endothelial cell–cell junctions and vascular integ-
rity, suggesting that by decreasing cell–cell adhesion and endothe-
lial integrity, endogenous Ang2 can facilitate the extravasation step 
at the endothelial cell–cell junctions. How Ang2 leads to the dis-
ruption of endothelial integrity remains to be elucidated. Such a 
mechanism may involve binding to integrins and loss of EC-EC 
junctional complexes, as reported for the related angiopoietin-like 
4 (Angptl4) protein (44).
Although we show that the Ang2-blocking antibodies inhibit 
metastasis in immunodeficient mice in the absence of inflamma-
tory  cell  contribution,  Ang2  also  affects  the  inflammatory  and 
immune responses in tumors (45,46). Ang2 has been reported to 
stimulate Tie2-expressing monocytes to suppress T-cell activa-
tion and to promote regulatory T-cell expansion (45). In tumor-
bearing  immunocompetent  mice,  Ang2-blocking  antibodies 
interfered with Tie2 expression in a subpopulation of macrophages 
and decreased angiogenesis, resulting in inhibition of metastasis 
(46). We found that the disruption of endothelial cell–cell and 
cell–matrix  contacts  in  metastatic  pulmonary  capillaries  was 
further  aggravated  in  an  immunocompetent  background,  sug-
gesting that the immune response can contribute to endothelial 
destabilization.
This  study  had  some  limitations.  We  used  rapidly  growing 
tumors. Thus, the conclusions may be strengthened with the use 
of genetically engineered mouse tumor models. The dose–response 
range was not evaluated, and because of the rapid tumor growth 
and  treatment  schedules,  possible  adverse  effects  related  to  the 
treatment may have gone unnoticed. In addition, it remains to be 
investigated if the Ang2 antibodies can inhibit metastatic colonization 
of other tissues besides the lungs.
Our results are in line with the previously proposed model in 
which Ang2 becomes initially overexpressed in the tumor co-opted 
blood vessels, leading to vessel destabilization. This increases hyp-
oxia in the tumor, and the expression of hypoxia-regulated VEGF 
and  Ang2  growth  factors,  inducing  robust  tumor  angiogenesis 
(47).  The  results  from  a  study  in  which  Ang2  was  ectopically 
expressed in a mammary carcinoma cell line also support a model 
of dual action of Ang2 in the tumors (48). In that study, Ang2 expres-
sion induced intratumoral hemorrhage, non-functional and abnor-
mal  blood  vessels,  and  was  associated  with  pericyte  loss  and 
increased endothelial cell apoptosis, possibly because of imbalance 
of  the  Ang2  and  VEGF  levels  in  the  tumors  (48).  It  has  been 
claimed that VEGFR2-targeted anti-angiogenic therapy increases 
metastatic frequency in some preclinical animal models (49). Our 
results showing that Ang2 induces vascular destabilization during 
tumor  metastasis  suggest  that  during  VEGF  blockade,  Ang2-
induced vascular destabilization could be associated with increased 
metastasis. Thus, combinatory therapy blocking both VEGF and 
Ang2 may provide more effective tumor growth and metastasis 
inhibition. 474   Articles | JNCI  Vol. 104, Issue 6  | March 21, 2012
In conclusion, we show that Ang2 contributes substantially to 
tumor progression and that blocking of Ang2 inhibits endothelial 
destabilization and constitutes an efficient strategy for inhibition of 
tumor growth and metastatic dissemination. Our data thus provide 
important new insights into the Ang2/Tie2 signaling pathway as an 
attractive target for cancer therapy.
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